Stock comparison
ELI LILLY & Co is 54.2x more valuable than Royalty Pharma plc by market capitalization ($1.146 T vs $21.16 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
LLY is larger
ELI LILLY & Co is 54.2x more valuable than Royalty Pharma plc by market capitalization ($1.146 T vs $21.16 B).
Market value leader
LLY
ELI LILLY & Co is 54.2x more valuable than Royalty Pharma plc by market capitalization ($1.146 T vs $21.16 B).
Revenue leader
LLY
RPRX: $2.38B vs LLY: $65.18B.
Profit leader
LLY
RPRX: $770.95M vs LLY: $20.64B.
Margin leader
RPRX
RPRX: 32.4% vs LLY: 31.7% net margin.
| Metric | RPRX | LLY |
|---|---|---|
| Market cap | $21.16 B | $1.146 T |
| US-listed rank | #608 | #10 |
| Revenue (latest FY) | $2.38B | $65.18B |
| Net income (latest FY) | $770.95M | $20.64B |
| Net margin | 32.4% | 31.7% |
| P/E (trailing FY) | 27.4x | 55.5x |
| SEC filings | 588 | 995 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
ELI LILLY & Co is 54.2x more valuable than Royalty Pharma plc by market capitalization ($1.146 T vs $21.16 B).
In their latest fiscal years, Royalty Pharma plc reported $2.38B in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Royalty Pharma plc and ELI LILLY & Co, or browse the full rankings.